Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial

Detalles Bibliográficos
Autores principales: Felizzi, F., Launonen, Aino, Thuresson, P.-O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929005/
https://www.ncbi.nlm.nih.gov/pubmed/36094634
http://dx.doi.org/10.1007/s41669-022-00366-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929005/
https://www.ncbi.nlm.nih.gov/pubmed/36094634
http://dx.doi.org/10.1007/s41669-022-00366-y

Ejemplares similares